Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema

Bissonnette, Robert; Worm, Margitta; Gerlach, B.; Guenther, Lyn; Cambazard, F.; Ruzicka, Thomas; Maares, J.; Brown, Thomas C.

doi:10.1111/j.1365-2133.2009.09572.x

Cited by 94 publications

(86 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our case the second and third therapeutic course of alitretinoin (30 mg daily) was necessary to completely heal the skin lesions. This is consistent with the data from a recently reported trial on chronic hand eczema [3] . The authors of this study demonstrated that alitretinoin at the dose of 30 mg daily reinduced response in the majority of patients who had relapsed within 6 months following successful treatment with an initial course of alitretinoin.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Gadaldi

Erdemoglu²,

Yawalkar³

2015

Dermatology

View full text Add to dashboard Cite

Background: Chronic itch with secondary scratch lesions such as prurigo has a major impact on quality of life. Due to its relapsing nature and often unknown origin, its treatment is challenging. Objective: We sought to demonstrate that alitretinoin can be an efficacious and well-tolerated treatment in a patient suffering from chronic itch with concomitant prurigo and psoriatic lesions. Methods: Case report. Results: After 1 month of alitretinoin treatment (30 mg daily), itch as well as prurigo and psoriasis lesions decreased markedly. Three cycles of alitretinoin were administered, as each cessation of treatment led to relapse of the symptoms after 6-8 weeks. Tapering of the alitretinoin dose (30 mg every second day) after the third cycle allowed to maintain the effects for over 18 months. Conclusion: Treatment of refractory prurigo with alitretinoin might be an efficacious alternative to standard therapies. In case of relapse, retreatment with alitretinoin reinduces a further long-lasting response.

show abstract

Section: Discussionsupporting

confidence: 83%

“…The most frequent adverse effects of alitretinoin include mucocutaneous dryness and headache [3] . The latter is dose dependent and often disappears with dose reduction.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Gadaldi

Erdemoglu²,

Yawalkar³

2015

Dermatology

View full text Add to dashboard Cite

show abstract

“…Although 9cRA appears to be a promising agent for prevention or treatment of prostate cancer on the basis of these results and animal data, clinical studies with 9cRA have demonstrated that oral intake is associated with dose-limiting side effects (Lawrence et al, 2001;Bissonnette et al, 2010). As a therapeutic agent, these side effects could be acceptable, but they render 9cRA unacceptable for prevention, particularly because the effects of retinoids are reversible (Esquenet et al, 1996) and sustained consumption would be necessary to maintain the protective effect.…”

Section: Discussionmentioning

confidence: 89%

Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells

Eskra

Kuiper²,

Walden³

et al. 2017

European Journal of Cancer Prevention

View full text Add to dashboard Cite

9-cis-Retinoic acid (9cRA), which binds to both retinoic acid receptors and retinoic X receptors, inhibits prostate cancer induction in rats and reduces growth of prostate cancer cells. However, the nature of this growth inhibition and the interactive influence of androgens are not well defined and are the subject of this report. LNCaP and PC-3 cells were cultured and treated with a range of 9cRA concentrations for 3-6 days in the absence or presence of 5α-dehydrotestosterone. 9cRA inhibited cell proliferation in a dose-dependent manner, plateauing at 10 mol/l. Treatment of cells with 10 mol/l 9cRA inhibited 5α-dihydroxytestosterone (DHT)-stimulated proliferation, the effect of which was maximal at 10 mol/l DHT. Treatment of DHT (10 mol/l)-exposed cells with 9cRA caused a dose-dependent increase in prostate-specific antigen in the medium after 6 days, but not 3 days. 9cRA caused a dose-dependent increase in apoptotic cells stained with H33258 after 3 days, but not 6 days; however, on using flow cytometry, apoptosis was apparent at both 3 and 6 days. Flow cytometry also revealed interference of G0/G1 to S phase transition by 9cRA. Inhibition by 9cRA of anchorage-independent growth of PC-3 cells was also found; LNCaP cells did not grow colonies in soft agar. 9cRA inhibited growth and induced differentiation of human LNCaP prostate cancer cells in vitro and inhibited anchorage-independent growth of PC-3 cells. Because 9cRA and 13-cis-retinoic acid, which is retinoic acid receptor-selective, prevent prostate carcinogenesis in rats, and 13-cis-retinoic acid also inhibits growth of human prostate cancer cells, the RAR is a potential molecular target for prostate cancer prevention and therapy.

show abstract

“…Stwierdzono całkowite lub prawie całko-wite ustąpienie zmian u 48% leczonych największą dawką (30 mg/dobę) w porównaniu z 28% pacjentów leczonych dawką 10 mg/dobę i 17% pacjentów z grupy otrzymujących placebo [27]. W 2009 roku przeprowadzono dodatkowe badanie oceniające skuteczność powtórnego włączenia terapii alitretynoiną u osób z nawracającym wypryskiem rąk i uzyskano obiecujące wyniki [28]. Wykazano również skuteczność leku w leczeniu odmian chłoniaków T--komórkowych skóry [29,30] oraz ziarniniaka ropotwórczego [31].…”

Section: Skuteczności Alitretynoinyunclassified

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Matejko¹,

Krêcisz²

2016

View full text Add to dashboard Cite

Przegląd Dermatologiczny 2016/5 StreSzczeniePrzewlekły wyprysk kontaktowy rąk to powszechne schorzenie, któ-re wywiera negatywny wpływ na funkcjonowanie i psychikę chorego. Stosowanie dostępnych, tradycyjnych metod leczniczych, takich jak miejscowe glikokortykosteroidy, inhibitory kalcyneuryny, fototerapia, leki immunosupresyjne, jest często niesatysfakcjonujące ze względu na brak zadowalającego rezultatu lub skutki uboczne. Alitretynoina (kwas 9-cis-retinowy) to aktywna substancja z grupy retinoidów zarejestrowana do ogólnoustrojowej terapii przewlekłego wyprysku kontaktowego rąk opornego na leczenie miejscowe. Jest agonistą zarówno receptorów RAR (receptory kwasu retinowego), jak i RXR (receptory X retinoidów) oraz pełni funkcję przeciwzapalną i immunomodulującą, ingerując w reakcję zapalną na różnych jej odcinkach. Dobra tolerancja leku oraz potwierdzona w badaniach klinicznych skuteczność terapeutyczna wskazują, że alitretynoina może być korzystną alternatywą leczniczą dla pacjentów z przewlekłym wypryskiem rąk opornym na inne formy terapii. AbStrActHand eczema is a common skin disorder with significant functional and economic impacts. Conventional therapy options, such as topical corticosteroids, calcineurin inhibitors, phototherapy and systemic immunosuppressants, often give unsatisfactory results, due to lack of efficacy or predominant adverse effects. Alitretinoin (9-cis-retinoic acid) is an active substance from the group of retinoids and is licensed as a systemic drug for chronic and severe hand eczema refractory to topical treatment. It binds with high affinity to both retinoic acid receptor (RAR) and retinoid X receptor (RXR) receptors and presents anti-inflammatory and immunomodulatory activity. Due to its good tolerance and high efficacy, demonstrated in several large clinical studies, alitretinoin may be an option for patients with severe chronic hand eczema refractory to other treatment. kontaktowe zapalenie skóry, wyprysk rąk oporny na leczenie, kwas 9-cis-retinowy, alitretynoina.

show abstract

Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema

Cited by 94 publications

References 10 publications

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells

Alitretinoin in treatment of chronic hand eczema – mechanism of action

Contact Info

Product

Resources

About